XML 103 R88.htm IDEA: XBRL DOCUMENT
v3.24.0.1

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) |  |  |  |  |  |  |  |  |  |  |  | 2 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2023 USD ($) | Oct. 01, 2023 USD ($) | Sep. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | Oct. 01, 2022 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Oct. 01, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) reporting_unit | Jun. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Mar. 31, 2022 reporting_unit | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 54,000,000 | $ 15,000,000 | $ 234,000,000
Impairment of Intangible Asset, Finite Lived, Statement of Income or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | impairments | impairments
Finite-lived intangible assets | $ 4,753,000,000 |  |  | $ 4,102,000,000 |  |  |  |  |  |  |  |  |  |  |  | 4,753,000,000 | $ 4,102,000,000 |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 493,000,000 | 824,000,000 |
Goodwill | 11,183,000,000 |  |  | 11,547,000,000 |  |  |  |  |  |  |  |  |  |  |  | 11,183,000,000 | 11,547,000,000 | $ 12,457,000,000
Accumulated goodwill impairment charges to date | 5,497,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,497,000,000 |  |
Salix |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |
Goodwill | 3,159,000,000 |  |  | $ 3,159,000,000 |  |  |  |  |  |  |  |  |  |  |  | 3,159,000,000 | $ 3,159,000,000 | 3,159,000,000
Dermatology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of reporting units | reporting_unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |
Uceris Foam |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  | $ 37,000,000 |  |  | 37,000,000 |  |
Xifaxan Branded Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets | 0 |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets | $ 2,155,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,155,000,000 |  |
Finite lived intangible assets, useful life | 48 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 48 months |  |
Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk | Salix |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 80.00% |  |
Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of reporting units | reporting_unit |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |
Generics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates | 1.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |
Reporting unit, impairment test, estimated cash flows, discount rate | 10.25% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.25% |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  |  |  |  |  |  | 40.00% |  |  |  |  |  |  |
Goodwill impairments | $ 91,000,000 |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |
Goodwill | 227,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 227,000,000 |  |
Dermatology Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  | 0.00% |  |  | 1.00% | 1.00% | 1.00% | 1.00% |  | 1.00% | 1.00% |  | 1.00% | 1.00% |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  | 10.75% |  |  | 10.50% | 10.00% | 9.00% | 9.00% |  |  | 10.00% |  | 10.50% | 9.00% |  |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  |  |  | 2.00% | 10.00% |  |  |  |  |  | 2.00% |  |  |
Goodwill impairments |  |  | $ 151,000,000 |  |  |  | $ 83,000,000 | $ 0 | $ 0 |  | $ 469,000,000 |  |  | $ 119,000,000 |  |  |  |
Reporting unit, impairment test, estimated cash flows, change in discount rate |  |  |  |  |  |  | 1.00% |  |  |  |  | 1.00% |  |  |  |  |  |
Goodwill | 329,000,000 |  | $ 329,000,000 |  |  | $ 480,000,000 |  |  |  |  |  |  |  | $ 480,000,000 |  | 329,000,000 |  |
Vision Care and Consumer Products, Pharmaceuticals and Surgical Reporting Units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  |  |  |  |  | 45.00% |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |
Vision Care, Surgical and Pharmaceuticals Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of fair value in excess of carrying value |  | 25.00% |  | 25.00% |  |  | 25.00% |  |  |  |  | 25.00% |  |  |  |  | 25.00% |
Goodwill impairments |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |
Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  | 2.50% |  |  |  |  |  |  |  | 2.50% |  |  |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  | 5.00% |  |  |  |
Goodwill impairments |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |
Neurology Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  | (2.50%) | (2.50%) |  |  |  |  |  |  |  |  |  |  |  |  | (2.50%) |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  | 10.50% | 10.25% |  |  |  |  |  |  |  |  |  |  |  |  | 10.25% |
Goodwill impairments |  |  | $ 251,000,000 |  | $ 622,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill | $ 1,177,000,000 |  | $ 1,192,000,000 | $ 1,439,000,000 |  |  |  |  |  |  |  |  |  |  |  | $ 1,177,000,000 | $ 1,439,000,000 |
International Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.00% |  |
Reporting unit, impairment test, estimated cash flows, discount rate | 12.75% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.75% |  |
Percentage of fair value in excess of carrying value | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75.00% |  |
Goodwill impairments | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum | Generics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  |  | 11.00% |  |  |  |  |  |  |
Minimum | Dermatology Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  |  | 9.00% |  |  |  |  |  |  |
Minimum | Vision Care and Consumer Products, Pharmaceuticals and Surgical Reporting Units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  | 7.00% |  |  |  |  |  |  |  |
Minimum | Vision Care, Surgical and Pharmaceuticals Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  | 2.00% |  | 2.00% |  |  | 2.00% |  |  |  |  | 2.00% |  |  |  |  | 2.00% |
Reporting unit, impairment test, estimated cash flows, discount rate |  | 10.25% |  | 9.50% |  |  | 9.00% |  |  |  |  | 9.00% |  |  |  |  | 9.50% |
Minimum | Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  | 9.75% |  |  |  |  |  |  |  | 9.75% |  |  |  |
Maximum | Generics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  |  | 12.25% |  |  |  |  |  |  |
Maximum | Dermatology Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |
Maximum | Vision Care and Consumer Products, Pharmaceuticals and Surgical Reporting Units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |
Maximum | Vision Care, Surgical and Pharmaceuticals Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  | 3.00% |  | 3.00% |  |  | 3.00% |  |  |  |  | 3.00% |  |  |  |  | 3.00% |
Reporting unit, impairment test, estimated cash flows, discount rate |  | 11.50% |  | 12.25% |  |  | 11.50% |  |  |  |  | 11.50% |  |  |  |  | 12.25% |
Maximum | Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  | 10.00% |  |  |  |
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 88,000,000
Trade Names No Longer Used |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,000,000 |  |
Discontinued Product Lines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,000,000 | $ 5,000,000 | 23,000,000
Product brands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 | 105,000,000
Finite-lived intangible assets | $ 4,336,000,000 |  |  | $ 3,644,000,000 |  |  |  |  |  |  |  |  |  |  |  | $ 4,336,000,000 | $ 3,644,000,000 |
Finite lived intangible assets, useful life | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |
Product brands | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite lived intangible assets, useful life | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |
Product brands | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite lived intangible assets, useful life | 20 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20 years |  |
Unutilized IT Infrastructure Improvement Project |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,000,000

X
- Definition Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag + References No definition available. + Details
Name: | bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
Namespace Prefix: | bhc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
Namespace Prefix: | bhc_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Long-Term Growth Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestLongTermGrowthRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details
Name: | us-gaap_GoodwillImpairedAccumulatedImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. + References No definition available. + Details
Name: | us-gaap_NumberOfReportingUnits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of fair value of reporting unit in excess of carrying amount. + References No definition available. + Details
Name: | us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_UcerisFoamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_GenericsReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_DermatologyReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_VisionCareAndConsumerProductsPharmaceuticalsAndSurgicalReportingUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndPharmaceuticalsReportingUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_NeurologyReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_InternationalReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_TradeNamesNoLongerUsedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |